Last scanned
Domain Age
Daily Visitors
Global Rank
Updated:
Medication to Reduce Cardiovascular Risk | PRALUENT® (alirocumab) Injection
Learn about PRALUENT, a PCSK9 inhibitor, that is approved to help reduce the risk of certain CV events in adults with established cardiovascular disease. Get access to ODYSSEY OUTCOMES trial data and read Important Safety Information on website.
This website is hosted with Intouch Group, LLC, which reserves the following IP addresses for praluenthcp.com: 192.103.124.92. Moreover, DNS used with this website include ns1.markmonitor.com, ns2.markmonitor.com, ns3.markmonitor.com, ns4.markmonitor.com, ns5.markmonitor.com, ns6.markmonitor.com, ns7.markmonitor.com. Subnet identifier ranges from 192.103.124.0 to 192.103.125.255. Classless Inter-Domain Routing (CIDR) is 192.103.124.0/23. ARIN net type is Direct Allocation.
Last scanned
Domain Age
Daily Visitors
Global Rank
ns1.markmonitor.com
ns2.markmonitor.com
ns3.markmonitor.com
ns4.markmonitor.com
ns5.markmonitor.com
ns6.markmonitor.com
ns7.markmonitor.com
{{value}}
2015-06-04
2024-06-04
MarkMonitor Inc.
{{value}}
The registrar of praluenthcp.com is MarkMonitor Inc. and the name expires on 2024-06-04. According to open source data, you can reach the owner at domains@regeneron.com but please make sure you have a good reason for unsolicited messages. Their country of residence is United States of America.
N/A
534
N/A
N/A
N/A
N/A
386.9K
N/A
N/A
N/A
N/A
534